There are a large number of drugs and treatment approaches for the treatment of epilepsy in clinical trials, from small molecules to genetic and surgical approaches. Pavel Klein, MD, Mid-Atlantic Epilepsy and Sleep Center, Bethesda, MD, outlines emerging epilepsy therapies currently under investigation. XEN1101 is an agonist of voltage-gated potassium ion channels that was recently shown to reduce focal-onset seizures in a placebo-controlled Phase II study (NCT03796962). Insights into the genetics of epilepsy have launched a revolution in genetic treatment approaches for rare forms of epilepsy such as Dravet syndrome and Lennox-Gastaut syndrome. There have also been important developments in acute rescue therapies, which are agents that can be administered rapidly once a clinical seizure or cluster of seizures starts. Ultimately, the development of novel epilepsy treatments might provoke a shift in the treatment of refractory epilepsy since a proportion of previously refractory patients might respond to the novel treatments. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).